Showing results (221-230 of 1,027) with videos related to

Sort By:
Pageof 103
Journal of Vascular Surgery|June 13, 2006
Stenting of vertebrobasilar arteries in symptomatic atherosclerotic disease and acute occlusion: case series and review of the literatureOlaf Eberhardt, Thomas Naegele, Sabine Raygrotzki, et al.
Neuro-Oncology|December 12, 2013
A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cellsFabian Wolpert, Isabel Tritschler, Alexander Steinle, et al.
International Journal of Molecular Sciences|October 23, 2021
Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic TargetNomi Zalcman, Mijal Gutreiman, Tal Shahar, et al.
Neuro-Oncology|September 18, 2012
Surgery for primary CNS lymphoma? Challenging a paradigmMichael Weller, Peter Martus, Patrick Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2020
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?Mustafa Khasraw, David A Reardon, Michael Weller, et al.
Cancer Treatment Reviews|January 6, 2017
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic reviewStephanie G C Kroeze, Corinna Fritz, Morten Hoyer, et al.
International Journal of Cancer|August 23, 2005
Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapyKhalil Zaman, Robert Driscoll, Diane Hahn, et al.
Ophthalmic Genetics|April 30, 2011
Chiasmatic infiltration secondary to late malignant transformation of retinomaAsimina Mataftsi, Leonidas Zografos, Aubin Balmer, et al.
Neuro-Oncology|February 16, 2026
Imaging Biomarkers for Detecting IDH-mutations and Monitoring Response to Novel Targeted Therapies: Current Insights and Future PerspectivesArchith Rajan, Felipe Rosero Castro, Laiz Laura de Godoy, et al.
BMC Cancer|May 26, 2020
Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigueClaudia Canella, Michael Mikolasek, Matthias Rostock, et al.
Pageof 103